CClinicalTrials.gg
CompletedNCT04335422Updated Jan 31, 2024

Effects of Robot-Assisted Upper Extremity Training on Cognitive and Physical Functions After Stroke

An interventional study of Robotic group (Upper extremity robot-assisted training plus routine physical and rehabilitation medicine program) and Control group (routine physical and rehabilitation medicine program) in Stroke, sponsored by Ankara University. Completed at 1 site in Turkey. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2024-01-31.

Sponsored by Ankara University · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Registered 7 months after the study started (first participant enrolled Sep 2019, registered Apr 2020).
Phase
Not applicable
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Study summary

Stroke is a main cause of disability worldwide. It is characterized by motor and cognitive impairments leading to activity limitations and participation restrictions. Despite improvement in mortality and morbidity following stroke, stroke survivors need access to effective rehabilitation services. Management approach for stroke survivors is classical physical and rehabilitation medicine (PRM) interventions. Nowadays, with the advancement of technology, robotic rehabilitation systems have taken its place among the classical physical and rehabilitation medicine applications. Robotic systems for upper and lower extremity help to improve neuroplasticity by repetitive task-specific activities. Upper extremity robotic systems can be either exoskeleton or end-effector according to their mechanical designs. Exoskeleton robotic systems attach to both proximal and distal segments of the upper extremity (shoulder, elbow, forearm, wrist, fingers) and provide antigravity weight support allowing actuated axes of movements of the upper extremity joints. The system allows the reinforcement and facilitation of movements by means of visual feedback with a 3-dimensional virtual environment in which the patient is asked to perform various tasks by playing computer games. It is reported that robotic therapy can be used complementary to other rehabilitation methods. The neurophysiological effects of robotic therapy were shown to act in the brain, particularly on the primary motor cortex, putamen and capsula interna. The effect on motor recovery was associated with common, synchronous activity involving the corticospinal system. It has been reported by a recent Cochrane review that robot-assisted arm training improves arm function, arm muscle strength and activities of daily living in stroke survivors. A few studies have also reported positive effects on cognitive abilities. However, there are no controlled studies in the literature investigating the effects of robot-assisted upper limb training on cognitive functions following stroke. The aim of this study was to investigate the effects of robot-assisted upper extremity training, applied in addition to the classical PRM program, on cognitive and physical functions after stroke. Primary aim is to investigate the effects on cognitive functions whereas secondary aim is to investigate the effects on upper extremity motor functions and activities of daily living. The investigators hypothesized that adjunctive robotic upper extremity training in addition to classical PRM program would result in better cognitive and physical outcomes compared with the classical PRM program only.

Read the detailed description

This study is planned as a prospective randomized single blind controlled study. It was approved by the Ethics Committee of Ankara University, Faculty of Medicine and will be conducted in accordance with the Declaration of Helsinki. The study will include 38 stroke survivors who are admitted for rehabilitation at the Department of Physical Medicine and Rehabilitation, Ankara University Medical Faculty. Patients fulfilling the inclusion criteria of the study will randomly be divided into 2 groups as robotic group and control group. Random allocation software (RAS) program will be used to assign the patients to the treatment groups with "block randomization" method and to create the randomization scheme. In this single blinded study, all patients will be evaluated by the same physician (Dr. Merve Dayi). The physician will be blind to patient's assignment. Routine physical and rehabilitation medicine program including physical therapy and exercises, walking and balance training, and occupational therapy to improve activities of daily living will be given to all patients for a total of 6 weeks, 5 days/week, 1 hour/day. Robotic group will additionally receive upper extremity robotic training therapy with Armeo Spring V2.0 exoskeleton (Hocoma Inc.,Zurich, Switzerland) for 6 weeks, 5 days/week, 1 hour/day. The Armeo Spring is an adjustable suspension system for the upper limb that connects to virtual reality, which has settings with several degrees of complexity. The system is an exoskeleton that supports the patient's arm and magnifies any residual active movement of the hemiparetic arm in 3-dimensional space. The patients will receive 30 sessions of robotic therapy under the supervision of physiotherapists, who will adjust the patient's arm and hand in the device and select the virtual reality computer games according to the functional level of the patient's upper limb. All individuals participating in the study will be assessed before and immediately after the treatment and also 3 months at follow-up. Each assessment will include evaluation of cognitive functions, upper extremity motor functions, hand dexterity, upper extremity activities and daily living activities.

Statistical Analysis

As the primary outcome variable, the difference in cognitive functions measured by the Montreal Cognitive Assessment Scale (MoCA) between baseline and post-treatment will be used (Δ MoCA). Group sample sizes of 19 and 19 achieve 80% power to detect a Δ MoCA of 2.4 between robotic and control groups with estimated group standard deviations of 2.5 and 2.5 and with a significance level of 0.05 using a two-sided Mann-Whitney U test. Stratified block randomization will be used to ensure an equal number of subjects in each group. Educational status and age has been chosen as stratification variables. Difference between two groups for continuous variables will be evaluated by Student's t test. Mann-Whitney U test will be used to assess difference between two groups in terms of ordinal variables. The differences in proportions between groups will be compared by using Chi-Square. The repeated-measures ANOVA will be used to test within-group and between-group comparisons for continuous variables and interaction between them. p\<0.05 will be considered statistically significant.

02

Conditions studied

  • Stroke

Browse trials for

Keywords

  • stroke
  • robotic
  • upper extremity
  • rehabilitation
03

In context

Stroke

7,286 studies on the registry are indexed under Stroke; 2,007 are open to participants now.

This study's enrollment of 40 is below the median of 50 across 5,369 interventional studies indexed under Stroke.

Browse Stroke studies →

Lead sponsor

Ankara University is the lead sponsor of 312 studies on the registry; 68 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Patients within the age range of 18-80 years
  • Patients with subacute stroke (post-stroke duration 1 month - 1 year)
  • Patients who have cognitive deficits and who can understand the commands to adapt to robotic training (MMSE ≤ 26)
  • Patients with first stroke attack
  • Patients who have never received robotic rehabilitation therapy
  • Patients with upper extremity (UE) Brunnstrom Stage III and above
  • Patients with a spasticity level below 3 (MAS 1-5 assessment system) according to the modified Ashworth Scale (MAS) in the affected upper extremity
  • Patients who agreed to participate in the study and signed the informed consent form

Exclusion criteria

Exclusion Criteria:

  • Patients who cannot understand commands or give informed consent
  • Patients without cognitive deficit (MMSE > 26)
  • Patients with aphasia
  • Patients who do not have sitting balance
  • Patients with unilateral neglect
  • Patients with unstable systemic medical diseases that may prevent the patient to receive robotic training sessions
  • Patients with psychiatric disorders
  • Patients with posterior cerebral artery infarction and subarachnoid hemorrhage
  • Patients with impaired vision that may affect robotic training
  • Patients with a peripheral nerve injury or musculoskeletal disease of the affected upper extremity
  • Patients who have pain in the affected upper extremity such that this pain might impede the patient to adapt to robotic training
  • Patients with involuntary abnormal movements (e.g. dystonia)
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
40 participants (actual)

Study arms

  • Experimental
    Robotic group

    Robotic group will receive both routine physical and rehabilitation medicine program and additional upper extremity robot-assisted training by Armeo Spring. Routine physical and rehabilitation medicine program, including physical therapy and exercises, walking and balance training, and occupational therapy to improve activities of daily living will last nearly 2 hours/day and robotic therapy one hour/day. Routine PRM program and robotic therapy will be given through 6 weeks, 5 days a week (A total of 30 sessions of routine PRM program plus robotic therapy).

    Device: Robotic group (Upper extremity robot-assisted training plus routine physical and rehabilitation medicine program) · Behavioral: Control group (routine physical and rehabilitation medicine program)

  • Active comparator
    Control group

    Control group will receive only routine physical and rehabilitation medicine program. Routine physical and rehabilitation medicine program, including physical therapy and exercises, walking and balance training, and occupational therapy to improve activities of daily living will last nearly 2 hours/day and will be given through 6 weeks, 5 days a week (A total of 30 sessions of routine PRM program only).

    Behavioral: Control group (routine physical and rehabilitation medicine program)

Interventions

  • DeviceRobotic group (Upper extremity robot-assisted training plus routine physical and rehabilitation medicine program)

    Upper extremity robot-assisted training will include facilitated shoulder flexion-extension, internal-external rotation, abduction-adduction, elbow flexion-extension, forearm supination-pronation, wrist flexion-extension, ulnar-radial deviation, hand finger flexion-extension movements by means of visual feedback with a 3-dimensional virtual environment in which the patient is asked to perform various tasks such as object reaching, grasping, holding, dropping activities by playing computer games. Routine physical and rehabilitation medicine program including physical therapy and exercises, walking and balance training, and occupational therapy to improve daily living activities will be given.

  • BehavioralControl group (routine physical and rehabilitation medicine program)

    Routine physical and rehabilitation medicine program including physical therapy and exercises, walking and balance training, and occupational therapy to improve daily living activities will be given.

06

What researchers measure

Primary outcomes

  1. Cognitive function

    Cognitive functions will be assessed by "Montreal Cognitive Assessment Scale (MoCA) " which evaluates visuospatial/executive functions, naming, memory, attention, language, abstraction and delayed recall. Total score ranges between 0 and 30. High scores are associated with better clinical outcomes.

    Time frame: change from baseline at 6 weeks and at 18 weeks

Secondary outcomes

  1. Upper extremity motor functions

    "Fugl - Meyer Upper Extremity Motor Rating Scale" will be used to evaluate the motor functions of the upper extremity. It includes 4 subheadings (upper extremity, wrist, hand, coordination/speed). Total score ranges between 0-66 with higher scores predict better outcome.

    Time frame: change from baseline at 6 weeks and at 18 weeks

  2. Hand dexterity

    "Box and Block Test" will be used for assessing manual dexterity. This test is composed of a wooden box divided into two compartments by partition and 150 blocks. The patients are instructed to move as many blocks as possible for a period of 60 seconds. Each hand is scored separately. Higher scores are indicative for better manuel dexterity.

    Time frame: change from baseline at 6 weeks and at 18 weeks

  3. Upper extremity function

    "The Motor Activity Log - 28 (MAG-28)" will be used to asses arm function. This instrument is a structured interview intended to examine how much and how well the subject uses his/her more-affected arm. Total score range between 0-5 and higher scores indicate better function.

    Time frame: change from baseline at 6 weeks and at 18 weeks

  4. Activities of Daily Living

    "Functional Independence Measure (FIM)" will be used to evaluate the functional status of patients in activities of daily living. The FIM's assessment of degree of disability depends on the patient's score in 18 categories, focusing on motor (self care, sphincter control, transfers, locomotion) and cognitive (communication, social cognition) function.

    Time frame: change from baseline at 6 weeks and at 18 weeks

07

Study locations

1 site
  • Ankara University
    Ankara, 06230, Turkey
08

References and documents

Related links

Individual participant data

Plan to share: No

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jan 31, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04335422
Lead sponsor
Ankara University
Responsible party
Ayşe A Küçükdeveci, MD (Professor of Physşcal Medicine and Rehabilitation, Ankara University) — Principal investigator
First posted
Apr 6, 2020
Start date
Sep 1, 2019
Primary completion
Jun 30, 2022
Completion
Jul 29, 2022
Last update
Jan 31, 2024

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion